Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study

被引：86

作者：

Staerk, L. ^{[1
]}

Gerds, T. A. ^{[2
]}

Lip, G. Y. H. ^{[3
,4
]}

Ozenne, B. ^{[2
]}

Bonde, A. N. ^{[1
]}

Lamberts, M. ^{[1
]}

Fosbol, E. L. ^{[5
]}

Torp-Pedersen, C. ^{[6
,7
]}

Gislason, G. H. ^{[1
,8
,9
,10
]}

Olesen, J. B. ^{[1
]}

机构：

[1] Copenhagen Univ Hosp Herlev & Gentofte, Dept Cardiol, Post 635,Kildegaardsvej 28, DK-2900 Hellerup, Denmark

[2] Univ Copenhagen, Sect Biostat, Dept Publ Hlth, Copenhagen K, Denmark

[3] Univ Birmingham, Inst Cardiovasc Sci, Birmingham, W Midlands, England

[4] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark

[5] Copenhagen Univ Hosp, Dept Cardiol, Rigshosp, Copenhagen O, Denmark

[6] Aalborg Univ, Dept Hlth Sci & Technol, Aalborg, Denmark

[7] Aalborg Univ Hosp, Dept Cardiol & Epidemiol Biostat, Aalborg, Denmark

[8] Danish Heart Fdn, Copenhagen, Denmark

[9] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen N, Denmark

[10] Univ Southern Denmark, Natl Inst Publ Hlth, Copenhagen K, Denmark

来源：

JOURNAL OF INTERNAL MEDICINE | 2018年 / 283卷 / 01期

关键词：

apixaban; atrial fibrillation; dabigatran; dose; NOAC; rivaroxaban; ANTAGONIST ORAL ANTICOAGULANTS; TEMPORAL TRENDS; WARFARIN; SAFETY; RISK; MORTALITY; EFFICACY;

D O I：

10.1111/joim.12683

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BackgroundComparative data of non-vitamin K antagonist oral anticoagulants (NOAC) are lacking in patients with atrial fibrillation (AF). ObjectiveWe compared effectiveness and safety of standard and reduced dose NOAC in AF patients. MethodsUsing Danish nationwide registries, we included all oral anticoagulant-naive AF patients who initiated NOAC treatment (2012-2016). Outcome-specific and mortality-specific multiple Cox regressions were combined to compute average treatment effects as 1-year standardized differences in stroke and bleeding risks (g-formula). ResultsAmongst 31 522 AF patients, the distribution of NOAC/dose was as follows: dabigatran standard dose (22.4%), dabigatran-reduced dose (14.0%), rivaroxaban standard dose (21.8%), rivaroxaban reduced dose (6.7%), apixaban standard dose (22.9%), and apixaban reduced dose (12.2%). The 1-year standardized absolute risks of stroke/thromboembolism were 1.73-1.98% and 2.51-2.78% with standard and reduced NOAC dose, respectively, without statistically significant differences between NOACs for given dose level. Comparing standard doses, the 1-year standardized absolute risk (95% CI) for major bleeding was for rivaroxaban 2.78% (2.42-3.17%); corresponding absolute risk differences (95% CI) were for dabigatran -0.93% (-1.45% to -0.38%) and apixaban, -0.54% (-0.99% to -0.05%). The results for major bleeding were similar for reduced NOAC dose. The 1-year standardized absolute risk (95% CI) for intracranial bleeding was for standard dose dabigatran 0.19% (0.22-0.50%); corresponding absolute risk differences (95% CI) were for rivaroxaban 0.23% (0.06-0.41%) and apixaban, 0.18% (0.01-0.34%). ConclusionsStandard and reduced dose NOACs, respectively, showed no significant risk difference for associated stroke/thromboembolism. Rivaroxaban was associated with higher bleeding risk compared with dabigatran and apixaban and dabigatran was associated with lower intracranial bleeding risk compared with rivaroxaban and apixaban.

引用

页码：45 / 55

页数：11

共 34 条

[1] Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study [J].